Saltz LB - Search Results

1

Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min.

Cercek A, Park V, Yaeger R, Reidy-Lagunes D, Kemeny NE, Stadler ZK, Segal NH, Varghese A, Saltz LB. Cercek A, et al. Among authors: saltz lb. J Oncol Pract. 2016 May;12(5):e548-53. doi: 10.1200/JOP.2015.008417. Epub 2016 Apr 12. J Oncol Pract. 2016. PMID: 27072569 Free PMC article.

2

Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, André AM, Grossano DD, Bertino JR. Conti JA, et al. Among authors: saltz lb. Cancer. 1995 Feb 1;75(3):769-74. doi: 10.1002/1097-0142(19950201)75:3<769::aid-cncr2820750304>3.0.co;2-5. Cancer. 1995. PMID: 7828126 Clinical Trial.

3

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C. Conti JA, et al. Among authors: saltz lb. J Clin Oncol. 1996 Mar;14(3):709-15. doi: 10.1200/JCO.1996.14.3.709. J Clin Oncol. 1996. PMID: 8622015

4

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.

Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP. Saltz LB, et al. J Clin Oncol. 1996 Nov;14(11):2959-67. doi: 10.1200/JCO.1996.14.11.2959. J Clin Oncol. 1996. PMID: 8918493 Clinical Trial.

5

9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.

Saltz LB, Kemeny NE, Tong W, Harrison J, Berkery R, Kelsen DP. Saltz LB, et al. Cancer. 1997 Nov 1;80(9):1727-32. doi: 10.1002/(sici)1097-0142(19971101)80:9<1727::aid-cncr5>3.0.co;2-b. Cancer. 1997. PMID: 9351540 Clinical Trial.

6

A phase II study of topotecan administered five times daily in patients with advanced gastric cancer.

Saltz LB, Schwartz GK, Ilson DH, Quan V, Kelsen DP. Saltz LB, et al. Am J Clin Oncol. 1997 Dec;20(6):621-5. doi: 10.1097/00000421-199712000-00018. Am J Clin Oncol. 1997. PMID: 9391553 Clinical Trial.

7

Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.

Saltz LB, Spriggs D, Schaaf LJ, Schwartz GK, Ilson D, Kemeny N, Kanowitz J, Steger C, Eng M, Albanese P, Semple D, Hanover CK, Elfring GL, Miller LL, Kelsen D. Saltz LB, et al. J Clin Oncol. 1998 Dec;16(12):3858-65. doi: 10.1200/JCO.1998.16.12.3858. J Clin Oncol. 1998. PMID: 9850031 Clinical Trial.

8

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Saltz LB, et al. N Engl J Med. 2000 Sep 28;343(13):905-14. doi: 10.1056/NEJM200009283431302. N Engl J Med. 2000. PMID: 11006366 Free article. Clinical Trial.

9

The role of irinotecan in colorectal cancer.

Saltz LB. Saltz LB. Curr Oncol Rep. 1999;1(2):155-60. doi: 10.1007/s11912-999-0027-1. Curr Oncol Rep. 1999. PMID: 11122813 Review.

10

A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.

O'Reilly EM, Stuart KE, Sanz-Altamira PM, Schwartz GK, Steger CM, Raeburn L, Kemeny NE, Kelsen DP, Saltz LB. O'Reilly EM, et al. Among authors: saltz lb. Cancer. 2001 Jan 1;91(1):101-5. doi: 10.1002/1097-0142(20010101)91:1<101::aid-cncr13>3.0.co;2-k. Cancer. 2001. PMID: 11148565 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

423 results

Search Page

Filters